This clinical study focuses on Type 2 Diabetes, a condition where the body has difficulty controlling blood sugar levels. The study aims to examine how different diabetes medications work in patients who have different characteristics of the disease – either reduced insulin effectiveness or decreased insulin production by the body. The medications being studied are dapagliflozin, which helps remove excess sugar through urine, and semaglutide, which helps the body produce more insulin when blood sugar levels are high.
The study will use various substances naturally present in the body (called biomarkers) to determine which patients might respond better to which medication. These biomarkers include substances like adiponectin, irisin, and others that can indicate how well the body processes sugar. The study will also measure standard indicators of diabetes control such as HbA1c (a measure of average blood sugar levels over time).
Participants in the study will be taking either dapagliflozin tablets or semaglutide tablets while continuing their usual metformin treatment. Some patients may also receive insulin glargine, which is given by injection under the skin. The study will monitor how these different treatments affect blood sugar control and other body functions related to diabetes.
Italy 
